Janus Henderson Small/Mid Cap Growth Alpha ETF
JSMD - ETF AI Analysis
Top Page
Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD)
JSMD, the Janus Henderson Small/Mid Cap Growth Alpha ETF, has a solid overall rating, largely driven by strong, profitable growth names like Maplebear (CART), Exelixis (EXEL), Medpace (MEDP), and Qualys (QLYS), which show robust financial performance, positive earnings commentary, and strategic initiatives that support future expansion. These strengths are partly offset by weaker holdings such as Equitable Holdings (EQH), which faces revenue declines, high leverage, and bearish trading trends, and by several positions with bearish momentum or valuation concerns, making the main risk factor the fund’s exposure to smaller growth companies that can be more volatile and sensitive to financial and technical setbacks.
JSMD vs. SPDR S&P 500 ETF (SPY)
- AUM
- 990.25M
- Region
- North America
- Expense Ratio
- 0.30%
- Beta
- 1.05
- Issuer
- Janus Henderson
- Inception Date
- Feb 23, 2016
- Dividend Yield
- 0.38%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
JSMD Summary
JSMD is the Janus Henderson Small/Mid Cap Growth Alpha ETF, focused on smaller U.S. companies with strong growth potential rather than following a traditional market index. It invests across many sectors, with a tilt toward technology and health care, and holds companies like CommVault Systems and Medpace Holdings. Someone might consider JSMD to seek higher long-term growth and diversify beyond large, well-known stocks. However, small and mid-sized growth companies can be more volatile, so the value of this ETF can go up and down more sharply than the overall market.
How much will it cost me?
JSMD has an expense ratio of 0.30%, which means you’ll pay about $3 per year for every $1,000 invested. This cost is a bit higher than many broad, passively managed index ETFs because JSMD is actively managed, aiming to pick specific small- and mid-cap growth stocks to try to outperform the market.
What would affect this ETF?
JSMD could benefit if the U.S. economy stays healthy and investors favor growth-oriented small and mid-sized companies, especially in technology and health care, where many of its holdings operate and innovation can drive strong business results. On the other hand, rising interest rates, economic slowdowns, or tighter regulations on tech, health care, or financial firms could hurt smaller companies more than large ones, increasing volatility and weighing on the ETF’s future performance.
JSMD Top 10 Holdings
JSMD leans heavily into U.S. growth stories in tech and health care, and a few names are clearly steering the ship. Cybersecurity player Qualys and biotech-focused Halozyme have been rising steadily, giving the fund a strong tailwind, while Medpace and Exelixis add more health care momentum with solid, if slightly overheated, runs. On the tech side, CommVault and Maplebear (Instacart) are climbing but show some mixed signals, hinting at pockets of volatility. Gen Digital, however, is losing steam, modestly dragging performance in an otherwise upbeat, domestically focused small/mid-cap lineup.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Concentra Group Holdings Parent, Inc. | 2.12% | $21.35M | $5.34B | 125.65% | 66Neutral | |
| Ryman | 2.11% | $21.25M | $9.11B | 44.19% | 66Neutral | |
| Maplebear | 2.04% | $20.56M | $13.75B | 66.15% | 79Outperform | |
| Gen Digital | 2.02% | $20.29M | $17.67B | 17.05% | 67Neutral | |
| CommVault Systems | 2.01% | $20.25M | $6.48B | 26.61% | 65Neutral | |
| Medpace Holdings | 1.98% | $19.93M | $18.27B | 10.29% | 79Outperform | |
| Exelixis | 1.96% | $19.71M | $16.98B | 70.51% | 78Outperform | |
| Equitable Holdings | 1.88% | $18.95M | $14.04B | 17.36% | 40Underperform | |
| Qualys | 1.73% | $17.41M | $6.59B | 29.51% | 78Outperform | |
| Lionsgate Studios | 1.73% | $17.41M | $4.24B | 102.56% | 52Neutral |
JSMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JSMD, the sentiment is Negative. The current price of 85.93 is below the 20-day moving average (MA) of 88.74, below the 50-day MA of 90.19, and below the 200-day MA of 90.11, indicating a bearish trend. The MACD of -0.85 indicates Positive momentum. The RSI at 40.30 is Neutral, neither overbought nor oversold. The STOCH value of 33.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSMD.
JSMD Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $85.93 | $92.00(7.07% Upside) | $990.25M | 0.30% | 66Neutral | |
| $27.09 | $33.20(22.55% Upside) | $716.89M | 0.75% | 68Neutral | |
| $57.10 | $70.42(23.33% Upside) | $683.87M | 0.62% | 64Neutral | |
| $32.92 | $40.42(22.77% Upside) | $453.14M | 0.68% | 70Outperform | |
| $24.11 | $35.73(48.20% Upside) | $379.05M | 0.75% | 69Neutral | |
| $32.01 | $40.91(27.81% Upside) | $365.74M | 0.38% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JSMD | Janus Henderson Small/Mid Cap Growth Alpha ETF | 85.93 | 1.91 | 2.28% | |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 27.09 | 1.36 | 5.29% | |
| MSSM | Morgan Stanley Pathway Small-Mid Cap Equity ETF | 57.10 | 7.30 | 14.67% | |
| CSMD | Congress SMid Growth ETF | 32.92 | 0.07 | 0.21% | |
| GRNJ | Fundstrat Granny Shots US Small- & Mid-Cap ETF | 24.11 | -0.19 | -0.78% | |
| ASCE | Allspring SMID Core ETF | 32.01 | 5.97 | 22.95% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
